Reig Jofre, member of CataloniaBio & HealthTech, has achieved significant success together with their partner Maruishi Pharmaceutical in Japan. They have produced in Barcelona and marketed in Japan 15 million vials of Remifentanil, a state-of-the-art intravenous anesthetic for hospital use. This product, internally developed by the company, is manufactured at Reig Jofre's sterile injectables and lyophilized plant.
The celebration of this success took place in Barcelona and was attended by delegations from the pharmaceutical companies that made it possible. Reig Jofre brings their expertise in the development and aseptic production of lyophilized injectable products, Kern Pharma contributes with their active ingredient synthesis capacity at their plant in Terrassa, Maruishi Pharmaceutical leads the project and brings their experience in hospital specialties in the field of intensive care units (ICU), assuming, together with Daiichi Sankyo, the commercialization of the anesthetic in the Japanese hospital network. In addition, CBC, experts in generating collaboration opportunities with Japan, in areas such as preoperative, infection control, and acute care, played a fundamental role in this success.
Reig Jofre's plants are responsible for 30% of the global supply of doses of this ultra-short-acting anesthetic that guarantees the necessary hemodynamic stability for optimal anesthesia control in surgical interventions. This anesthetic does not accumulate in the body, allowing for rapid patient recovery in the postoperative period.
The company plans to continue supplying this anesthetic to Japan in the coming years and continue growing with market demand, thanks to Maruishi's experience and knowledge in this field, supported by the exceptional relationship of trust and collaboration between both companies. Internationalization represents one of the fundamental strategic pillars in Reig Jofre's expansion.
Specialization in the development and aseptic production of sterile injectable drugs for hospital use, mostly developed by R&D teams, has been one of the key elements in the company's global expansion. Currently, approximately 60% of revenue comes from operations outside of Spain, with a strong presence in Europe through their own teams in France, Belgium, Portugal, Sweden, Poland, and the United Kingdom, and the trust of an extensive network of 160 commercial partners in over 70 countries worldwide.
Comments